Study S000192

A Phase Ib Clinical Trial, Using Interleukin-2 (IL-2) and Semaglutide in Patients With Alzheimer's Disease

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT07651319
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1; PHASE2
Masking: QUADRUPLE
Status: RECRUITING
Enrollment: 30
Start: 2026-09-01
Primary completion: 2029-06
Lead sponsor: The Methodist Hospital Research Institute
Conditions: Alzheimer Dementia (AD)
Interventions: DRUG:IL-2 (Aldesleukin); DRUG:Semaglutide Plus IL-2; DRUG:Placebo
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

Safety and the tolerability of IL-2 plus Semaglutide in AD patients [6 months treatment phase]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.